“The strong growth in e-commerce and in product segments outside the pharmaceutical benefits system is affecting market dynamics, and TLV is monitoring developments closely,” says Harald Ström, head of unit at TLV, in a press release.
Pharmacy sales amounted to SEK 71 billion last year and are expected to continue rising in the coming years. By 2028, sales are expected to reach around SEK 83 billion.
“Prescription drugs outside the pharmaceutical benefits system, including drugs for obesity, are particularly expected to continue growing rapidly,” the report states.
TLV has repeatedly rejected requests to include weight-loss drugs such as Wegovy, made by the Danish company Novo, in the benefits system.








What do you think?